Speaker: Paul Reading, PhD, Clinical Neurologist, Department of Neurology, Newcastle General Hospital, Newcastle-Upon-Tyne, United Kingdom. Results from an open-exploratory study point out that the cholinesterase inhibitor rivastigmine (Exelon, Novartis) has a positive effect on the neuropsychiatric complications of Parkinson’s disease (PD), particularly hallucinations and sleep disturbances, and significantly enhances cognitive performance without worsening motor control.

Continue reading " American Academy of Neurology: Cholinesterase Inhibitor for Parkinsonian Neuropsychiatric Symptoms "

Speaker: Jose Ferreira, MD, Pediatric Epilepsy Neurologist, Pediatric Epilepsy and Neurology Specialists, Tampa, Florida. Topiramate (Topamax medication, Ortho-McNeil), a broad-spectrum antiepileptic, appears to be efficacious and generally well­tolerated in pediatric and adolescent migraine prophylaxis, substantially reducing migraine headache frequency and severity and improving the disability associated with migraine.

Continue reading " American Academy of Neurology: Antiepileptic for Pediatric and Adolescent Migraine Prophylaxis "

Combination Therapy for Relapsing-Remitting MS Speaker: Silva Markovic-Plese, MD, Clinical Fellow, Neuroimmunology Branch, the National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland. Interferon beta-1b (INF-beta-1b) (Betaseron, Berlex) and azathioprine (Imuran drug, Prometheus) combination therapy appears to offer an effective treatment approach in patients with relapsing-remitting multiple sclerosis (RRMS) who are [...]

Continue reading " American Academy of Neurology "